This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Atrial fibrillation and driving

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Arrhythmias include:

  • sinoatrial disease
  • significant atrioventricular conduction defect
  • atrial flutter/fibrillation
  • narrow or broad complex tachycardia

Note:

  • transient Arrhythmias occurring during acute coronary syndromes do not require assessment under this Section

Regarding group 1 entitlement:

  • Must not drive if arrhythmia has caused or is likely to cause incapacity.
  • Driving may resume without DVLA notification only after:
    • underlying cause has been identified
    • arrhythmia is controlled for at least 4 weeks
  • Must notify the DVLA if there are distracting or disabling symptoms and/or arrhythmia is not controlled for at least 4 weeks, and an underlying cause has not been identified.

Regarding group 2 entitlement:

  • Must notify the DVLA.
  • Must not drive if arrhythmia has caused or is likely to cause incapacity.
  • Licence will be refused or revoked.
  • May be relicensed/licensed (provided there is no other disqualifying condition) only after:
    • underlying cause has been identified
    • arrhythmia has been controlled for at least 3 months
    • LV ejection fraction is at least 40%.

Up-to-date guidance may be obtained from the publication "At a Glance Guide to the Current Medical Standards of Fitness to Drive" and the website www.dvla.gov.uk

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.